Johnson & Johnson 향후 성장

Future 기준 점검 1/6

Johnson & Johnson (는) 각각 연간 1% 및 5.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 1.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 31.3% 로 예상됩니다.

핵심 정보

1.0%

이익 성장률

1.44%

EPS 성장률

Pharmaceuticals 이익 성장	13.8%
매출 성장률	5.1%
향후 자기자본이익률	31.34%
애널리스트 커버리지	Good
마지막 업데이트	12 Dec 2025

최근 향후 성장 업데이트

Recent updates

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 12

Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

May 21

이익 및 매출 성장 예측

NYSE:JNJ - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	103,269	23,371	23,256	30,299	21
12/31/2026	98,475	22,400	22,744	28,695	24
12/31/2025	93,756	24,777	18,722	29,329	22
9/28/2025	92,149	25,119	18,679	24,204	N/A
6/29/2025	90,627	22,661	16,397	23,028	N/A
3/30/2025	89,331	21,810	18,574	24,783	N/A
12/29/2024	88,821	14,066	18,059	24,266	N/A
9/29/2024	87,696	14,767	19,025	25,146	N/A
6/30/2024	86,576	16,382	19,833	24,642	N/A
3/31/2024	85,648	17,072	18,234	23,191	N/A
12/31/2023	85,159	13,326	17,778	22,791	N/A
10/1/2023	83,703	12,421	15,737	20,278	N/A
7/2/2023	82,348	12,422	14,547	19,073	N/A
4/2/2023	77,458	10,730	16,207	20,472	N/A
1/1/2023	79,990	16,370	17,185	21,194	N/A
10/2/2022	84,855	17,879	17,739	21,576	N/A
7/3/2022	88,197	17,236	19,950	23,582	N/A
4/3/2022	94,880	19,830	19,733	23,315	N/A
1/2/2022	78,740	17,801	19,758	23,410	N/A
10/3/2021	91,446	17,880	22,461	26,021	N/A
7/4/2021	89,190	17,767	22,564	26,114	N/A
4/4/2021	84,214	15,115	20,853	24,252	N/A
1/3/2021	82,584	14,714	20,189	23,536	N/A
9/27/2020	80,856	16,986	18,307	21,591	N/A
6/28/2020	80,503	15,185	17,443	20,735	N/A
3/29/2020	82,729	17,166	19,764	23,231	N/A
12/29/2019	82,059	15,119	19,918	23,416	N/A
9/29/2019	81,706	14,151	19,706	23,262	N/A
6/30/2019	81,325	16,332	N/A	22,007	N/A
3/31/2019	81,593	14,679	N/A	22,138	N/A
12/30/2018	81,581	15,297	N/A	22,201	N/A
9/30/2018	81,382	1,542	N/A	22,062	N/A
7/1/2018	80,684	1,372	N/A	22,056	N/A
4/1/2018	78,693	1,245	N/A	21,749	N/A
12/31/2017	76,450	1,300	N/A	21,056	N/A
10/1/2017	74,361	15,827	N/A	21,604	N/A
7/2/2017	72,531	16,335	N/A	20,699	N/A
4/2/2017	72,174	16,505	N/A	19,491	N/A
1/1/2017	71,890	16,540	N/A	18,767	N/A
10/2/2016	71,595	15,941	N/A	17,199	N/A
7/3/2016	70,877	15,027	N/A	17,978	N/A
4/3/2016	70,182	15,546	N/A	18,886	N/A
1/3/2016	70,074	15,409	N/A	19,569	N/A
9/27/2015	70,517	14,715	N/A	18,849	N/A
6/28/2015	71,882	16,106	N/A	17,363	N/A
3/29/2015	73,590	15,916	N/A	17,420	N/A
12/28/2014	74,331	16,323	N/A	18,710	N/A

애널리스트 향후 성장 전망

수입 대 저축률: JNJ 의 연간 예상 수익 증가율(1%)이 saving rate(3.3%) 미만입니다.

수익 vs 시장: JNJ 의 연간 수익(1%)이 US 시장(16.1%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: JNJ 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: JNJ 의 수익(연간 5.1%)이 US 시장(연간 10.6%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: JNJ 의 수익(연간 5.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: JNJ의 자본 수익률은 3년 후 31.3%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/15 17:46
종가	2025/12/12 00:00
수익	2025/09/28
연간 수익	2024/12/29

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Johnson & Johnson는 53명의 분석가가 다루고 있습니다. 이 중 24명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Matthew Miksic	Barclays
Joanne Wuensch	BMO Capital Markets Equity Research

Johnson & Johnson 향후 성장

Future 기준 점검 1/6

핵심 정보

최근 향후 성장 업데이트

Johnson & Johnson Raises Earnings Guidance for 2025

Consensus EPS estimates increase by 11%

Recent updates

Johnson & Johnson Announces U.S. Food and Drug Administration Approves AKEEGA as the First Precision Therapy for BRCA2-Mutated Metastatic Castration-sensitive Prostate Cancer with 54% Reduction in Disease Prostate Cancer with 54% reduction in Disease Prostate Cancer

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Hagens Berman Sobol Shapiro LLP and Lowey Dannenberg, P.C. Announce Certification of a Class of Third Party Payors Who Purchased or Paid for Some or All of the Price of Stelara

Johnson & Johnson Announces Updated Results For CARVYKTI In Relapsed Or Refractory Multiple Myeloma

Johnson & Johnson's INLEXZO Delivers 74% Disease-Free Survival at One Year in Bcg-Unresponsive, High-Risk, Papillary-Only NMIBC

Johnson & Johnson (NYSE:JNJ) signed a definitive agreement to acquire Halda Therapeutics Opco, Inc. for $3.0 billion.

FDA Approves Darzalex Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of Caplyta (Lumateperone)

Johnson & Johnson Announces Week 28 Results from Phase 2b ANTHEM-UC Study of Icotrokinra

Johnson & Johnson Announces Findings from the Phase 2 Dahlias Study

Johnson & Johnson Announces New Long-Term Results from the Phase 3 ICONIC-TOTAL Studya Evaluating icotrokinra

Insider notifies of intention to sell stock

Third quarter dividend of US$1.30 announced

TECVAYLI® plus DARZALEX FASPRO® Combination Regimen Significantly Improves Progression-Free Survival and Overall Survival Versus Standard of Care

Johnson & Johnson Declares Dividend for the Fourth Quarter of 2025, Payable on December 9, 2025

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Johnson & Johnson Raises Earnings Guidance for 2025

Johnson & Johnson to Showcase New Clinical and Real-World Data on Major Depressive Disorder Portfolio At 2025 ECNP Congress

New major risk - Revenue and earnings growth

Johnson & Johnson Announces TREMFYA® (Guselkumab) Is First and Only Il-23 Inhibitor to Demonstrate Sustained Clinical and Endoscopic Outcomes with A Fully Subcutaneous Regimen Through 48 Weeks in Ulcerative Colitis

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Tremfya®? (Guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arritis

Johnson & Johnson Announces U.S. Approval for Subcutaneous Indication in Adults with Ulcerative Colitis

Johnson & Johnson Announces an Investigational Immune-Based Indication Regimen with TECVAYLI®? (Te) and DARZALEX FASPRO®? (Daratumumab andhyaluronidase-fihj) Demonstrated Clinical Trial

Johnson & Johnson Announces New Data from the Phase 3 ICONIC-ADVANCE 1 and 2 Studies

Johnson & Johnson to Showcase Neuropsychiatry Innovations at the 2025 Psych Congress Annual Meeting

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Inlexzo™? (Gemcitabine Intervesical System) Set to Transform How Certain Bladder Cancersare Treated

Johnson & Johnson Elects John Morikis to its Board of Directors and Audit Committee and Compensation & Benefits Committee

Johnson & Johnson Announces Data Publishes in the New England Journal of Medicine Demonstrate RYBREVANT (Amivantamab-Vmjw) Plus LAZCLUZE (Lazertinib) Is Re-Setting Survival Expectations in First-Line EGFR-Mutated Lung Cancer

Johnson & Johnson Announces New Analyses from the Phase 3 Mariposa Study Showing That First-Line Treatment with RYBrevant (Lazertinib) Plus Lazertinib

Johnson & Johnson to Report Q4, 2025 Results on Jan 21, 2026

Johnson & Johnson Unveils Results from the Varipure Substudy of Secure, a Real-World Study on Varipure™? Platform, at 2025 European Society of Cardiology (ESC) Congress

Johnson & Johnson Announces New Data from the DanGer Shock Randomized Control Trial, Published in the New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

Upcoming dividend of US$1.30 per share

Executive VP & CFO notifies of intention to sell stock

Boston Jury Hits Johnson & Johnson with Record $42 Million Verdict in Asbestos Baby Powder Case

Johnson & Johnson Files with U.S. FDA to Include New Evidence in TREMFYA®? (Guselkumab) Label as the Only IL-23 Inhibitor to Demonstrate Significant Inhibitor to Demonstrate Significant Inhibitor of Joint Structural Damage in Active Psoriatic Arthritis

New minor risk - Financial position

Johnson & Johnson Showcases Latest Advancements in Alzheimer's Research At AAIC 2025

New major risk - Revenue and earnings growth

Johnson & Johnson Announces Submission of New Drug Application to the U.S. Food and Drug Administration

Insider recently sold US$3.1m worth of stock

Insider notifies of intention to sell stock

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Johnson & Johnson Receives U.S. Fda Priority Review for Tar-200 Nda in High-Risk Non-Muscle Invasive Bladder Cancer

New major risk - Revenue and earnings growth

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025, Payable on September 9, 2025

Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia

Johnson & Johnson Announces New Data from an Indirect Treatment Comparison

Johnson & Johnson Hit with $8 Million Verdict in Massachusetts Mesothelioma Talc Lawsuit

Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma

Johnson & Johnson Announces New Data Showing TREMFYA® Significantly Inhibits Progression of Joint Structural Damage in Active Psoriatic Arthritis

Johnson & Johnson Appoints Daniel Pinto to the Board of Directors, Effective July 1, 2025

Johnson & Johnson Announces Data from Two Studies Highlighting DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj)

Johnson & Johnson Unveils First-In-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

Johnson & Johnson to Report Q3, 2025 Results on Oct 14, 2025

Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Approves the Approval of the Benefit-Risk Profile of Single- Agent Darzalex Faspro®?

Upcoming dividend of US$1.30 per share

Jury Orders Johnson & Johnson to Pay $3 Million in Mesothelioma Death of New Orleans Woman

Johnson & Johnson Announces New Data from the Phase 3 ASTRO Study Evaluating TREMFYA (Guselkumab) Subcutaneous (SC) Induction Therapy in Adults with Moderately to Severely Active Ulcerative Colitis (UC)

Johnson & Johnson (NYSE:JNJ) Is Increasing Its Dividend To $1.30

Johnson & Johnson Announces Retirement of D. Adamczyk from the Board of Directors, May 31, 2025

Johnson & Johnson Receives FDA Approval for IMAAVY™? (Nipocalimab-Aahu)

Johnson & Johnson Announces New Data from Cohort 2 of the Pivotal Phase 2b SunRISe-1 Study Evaluating TAR-200

Johnson & Johnson Just Proved The Bears Wrong Again

Consensus EPS estimates increase by 11%

Johnson & Johnson Unveils Highly Anticipated and Potential Practice-Changing Data in Bladder Cancer Treatment At American Urological Association

Johnson & Johnson (NYSE:JNJ) Is Paying Out A Larger Dividend Than Last Year

First quarter dividend increased to US$1.30

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Johnson & Johnson Increases Quarterly Dividend, Payable on June 10, 2025

Johnson & Johnson Announces New Icotrokinra (Jnj-2113) Data from A Subgroup Analysis of Iconic-Leada

Johnson & Johnson Highlights New Data That Showcases the Strength of Nipocalimab, Demonstrating Long-Term Sustained Disease Control in Adults Living with Generalized Mg (gMG)